Mereo Downgraded by JP Morgan on Setrusumab Risk JP Morgan downgraded Mereo to Neutral on Mar 23, 2026 citing setrusumab regulatory uncertainty; EMA reviews average 210 days and FDA reviews ~6–10 months (Seeking Alpha; EMA; FDA).

Mereo Downgraded by JP Morgan on Setrusumab Risk: JP Morgan downgraded Mereo to Neutral on Mar 23, 2026 citing setrusumab regulatory uncertainty; EMA reviews average 210 days and FDA reviews ~6–10 months (Seeking Alpha; EMA; FDA). 👈 Read full analysis #Mereo #JPMorgan #Setrusumab #FDA #EMA